Arthur Aung

Hematology Oncology Fellow | Northwell Health Northshore/LIJ Hospital

[Arthur Aung @Arthur_Aung]

@JCOOP_ASCO One question that emerged from this work:

Should our assessment of tolerability extend beyond adverse events to include a patient's ability to remain on therapy long enough to derive benefit?

#ProjectOptimus #LCSM

[Arthur Aung @Arthur_Aung]

Excited to share our systematic review and meta-analysis of standard- versus reduced-dose sotorasib in KRAS G12C-mutated NSCLC, now published in @JCOOP_ASCO

Reduced dosing did not appear to substantially compromise efficacy, supporting dose optimization efforts aligned with FDA Project Optimus.

Grateful to my coauthors for their contributions to this work.

@NagashreeSeeth1 @DivyaReddyMD @KRASKickers
#KRAS #ProjectOptimus #LCSM
https://t.co/c0pEd8KjBN

[Arthur Aung @Arthur_Aung]

Completely agree. Tolerability is more than adverse events. If reduced toxicity allows patients to stay on treatment longer without compromising target inhibition, it may become part of the efficacy pathway itself.

Grateful to @HannahRAbrams for highlighting this concept and to @NagashreeSeeth1 for her mentorship on the work behind these observations.

[Hannah Abrams, MD @HannahRAbrams]

In this regard, drugs like Zofran, interventions like exercise, etc, are some of the most powerful cancer Rx we have. So kudos @Arthur_Aung on this study - higher upfront dose intensity is not always most effective if can’t consistently deliver it safely!

[Arthur Aung @Arthur_Aung]

@HannahRAbrams @JCOOP_ASCO @KRASKickers @NagashreeSeeth1 Thank you @HannahRAbrams. It raises an interesting question: should our assessment of tolerability extend beyond adverse events to include a patient's ability to remain on therapy long enough to derive benefit?

[Arthur Aung @Arthur_Aung]

Excited to see this work presented at #ASCO26. Patients with pre-existing autoimmune disease remain underrepresented in immunotherapy trials, and real-world data are critical to informing treatment decisions. Looking forward to seeing the results and discussion.
@NehemiasGuevar5 @dominicandoc2 @oncodaily

[Abner Antonio Murray, MD PhD @dominicandoc2]

Congrats to @NehemiasGuevar5 & team #ASCO26

Key takeaways for oncologists:
🔹 Autoimmune disease ≠ automatic exclusion from ICIs
🤔 Requires careful toxicity monitoring & patient selection
🤝 Strong oncology + rheumatology collaboration is critical
🔹 Shared decision-making remains essential

Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO

[Abner Antonio Murray, MD PhD @dominicandoc2]

Congrats to @NehemiasGuevar5 & team #ASCO26

Key takeaways for oncologists:
🔹 Autoimmune disease ≠ automatic exclusion from ICIs
🤔 Requires careful toxicity monitoring & patient selection
🤝 Strong oncology + rheumatology collaboration is critical
🔹 Shared decision-making remains essential

Important real-world data for everyday practice 💉🫁 #Immunotherapy @ASCOTECAG @hemeoncfellow @HemOncFellows @ASCO

[Arthur Aung @Arthur_Aung]

Thank you @NarjustFlorezMD for building such a supportive community for trainees and early-career oncologists. It’s a great reminder of how much mentorship and community can shape our careers. @NehemiasGuevar5 #ASCO26

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

My joy and pride - the community that I once created so nobody will feel as isolated as once did.

At our yearly lunch at #ASCO26

[Ashish Samaddar, MD @SamaddarMD]

What environmental factors may contribute to lung cancer risk beyond smoking?

Looking forward to presenting our #ASCO26 poster on ambient carbon tetrachloride exposure and lung cancer incidence in the U.S.

Abstract: https://t.co/4lxoYo7Wv4

@NagashreeSeeth1 @NorthwellHealth

[Arthur Aung @Arthur_Aung]

As oncology becomes increasingly complex, patient education is more important than ever.

I'm grateful for the opportunity to work with @cancerGRACE on a patient education series focused on #ThyroidCancer, covering
🧬 Targeted therapies
🩺 Treatment pathways
📈 Management of recurrent thyroid cancer

Video 30-32
https://t.co/li38QJywrX

Translating rapidly evolving science into practical information for patients and caregivers remains an essential part of delivering high-quality cancer care.

If you're in Chicago for #ASCO26, join us at the GRACE reception:

📍 Beatrix North
📅 May 29
🕖 7 PM
#ThyroidCancer #PatientEducation #ASCO26
@NagashreeSeeth1 @JackWestMD @AmyBickleman @NehemiasGuevar5 @oncodaily @EliLillyandCo @ASCOTECAG

[Nagashree Seetharamu, MD, FASCO @NagashreeSeeth1]

Now focusing on the rapid oral abstract head and neck cancers (Monday 6/1 at 4:30 PM CT)- a fascinating line up featuring novel therapeutics and strategies-hinting towards a brighter future

[Liang Chang @liangc_science]

I used a team of ~30 AI agents to analyze 57,603 ASCO Abstracts between 2016-2025. Here are my top 6 learnings on the past decade of oncology https://t.co/nuE5shJhtw

[Nehemias Guevara-Rodriguez @NehemiasGuevar5]

Excited to share our new publication with @NarjustFlorezMD @MImbimbo1 @COlazagasti on lung cancer diagnosed during pregnancy — a rare and highly complex clinical scenario requiring multidisciplinary care.
https://t.co/lBRZTslF8h

[Abner Antonio Murray, MD PhD @dominicandoc2]

Conference season is upon us with poster sessions, #oralabstracts, and #grandrounds on the horizon! To help prepare, we wrote this #ASCOconnection article:

🔗 The High-Stakes Talk 🗣️ @jennifermarksmd @ASCO
In the piece, we share practical strategies to:
🔹 Lead with the core message
🔹 Make the “so what” clear
🔹 And more

Because strong science should be easy to understand, discuss, remember, and carry forward.

🙋🏾‍♂️What is the best presentation advice you have received or the one lesson you wish you had learned earlier?

https://t.co/AxkLPao6Km

#Oncology #MedEd #ASCOtips #PresentationTips #PosterPresentation #ResearchTalks

@hemeoncfellow @HemOncFellows @SNMA @LmsaNational @ASCOTECAG @OncoAlert @oncodaily

[#TumorBoardTuesday @TumorBoardTues]

#TumorBoardTuesday
🫁 Early-stage #NSCLC is no longer just surgery ➕ chemo: Molecular testing now shapes curative-intent Tx decisions 🧬
📢Join us Tuesday, 05-05-26 at 8PM ET as @NarjustFlorezMD & @NehemiasGuevar5 🗣️EGFR+ Early #NSCLC
RT and bring others into the discussion‼️

[Nehemias Guevara-Rodriguez @NehemiasGuevar5]

Join us tomorrow at 8 PM ET for a deep dive into early-stage #NSCLC and #NeoADAURA @TumorBoardTues @NarjustFlorezMD @Florez_Lab @OncBrothers @COlazagasti @dominicandoc2 @oncodaily @Arthur_Aung
@guicorreiamd
@IMG_Oncologists @Shuai_WangOnc @HyeinJeon_MD @TejaVorugantiMD @OncLive

[Arthur Aung @Arthur_Aung]

Honored to contribute to the discussion on thyroid cancer in 2026. Thank you to @oncodaily @NagashreeSeeth1 @DrMLChua @amanda_psyrri for organizing the summit.

[OncoDaily @oncodaily]

Highlights From How I Treat Head and Neck Cancers in 2026: OncoDaily Virtual Summit

@COlazagast @AriRosenbergMD @NagashreeSeeth1 @mdkarapetyan @drdavidpalma @amil__dr @amanda_psyrri @drdaviddwlee @imrtlee @DrMLChua

https://t.co/MRDbR0QTCP

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter #HeadAndNeckCancer

[Arthur Aung @Arthur_Aung]

Great catching up with @JackieAredoMD and soon-to-be faculty @TLCconference. #TexasLung

[Arthur Aung @Arthur_Aung]

Amazing panel discussion on long-term immunotherapy outcomes in NSCLC, dual checkpoint blockade, and how we still need to refine patient selection. Grateful to learn from this group
@benlevylungdoc
@lungoncdoc @RachelSanbornMD @DasMillie11 #TexasLung